(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 1,549.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.31%, and it is also forecast to beat the US market's average forecast revenue growth rate of 22.77%.
Argenx Se's revenue in 2026 is $1,917,647.On average, 31 Wall Street analysts forecast ARGX's revenue for 2026 to be $359,613,518,184, with the lowest ARGX revenue forecast at $268,611,523,002, and the highest ARGX revenue forecast at $437,371,091,532. On average, 27 Wall Street analysts forecast ARGX's revenue for 2027 to be $438,652,809,774, with the lowest ARGX revenue forecast at $337,641,205,464, and the highest ARGX revenue forecast at $580,252,158,414.
In 2028, ARGX is forecast to generate $527,335,505,280 in revenue, with the lowest revenue forecast at $448,601,384,700 and the highest revenue forecast at $642,384,976,050.